REYVOW is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use: REYVOW is not indicated for the preventive treatment of migraine.
Lilly is hosting a webcast series on REYVOW (lasmiditan) C-V. These webcasts are being offered on several dates at different times, so you can choose one that’s convenient for you. All you need is an Internet connection and a phone, computer, or tablet to participate.
Join us to learn more about how REYVOW works, how to prescribe it, and how to identify which of your adult patients can benefit from this treatment option.
The webinar covers important pharmacy laws enacted by the Legislature that took effect this year. The program replaces the previous webinar on 2019 Pharmacy Law, which remains posted online for reference.
California Code of Regulations, title 16, section 1732.5(b) requires that at least two of the 30 hours of CE required for renewal of a pharmacist license be completed by participating in law and ethics courses provided by the Board of Pharmacy. The requirement applies to pharmacists whose licenses expired on or after July 1, 2019.
In addition to the law webinar, a CE webinar on ethics is available on the Board’s website. Each webinar meets one hour of the two hours required for law and ethics CE courses provided by the Board. Pharmacists may view the video webinars anytime. Registration is not required.
Both law and ethics videos are posted on the Law and Ethics Webinar page on the Board’s website. A link to the 2020 Law Webinar also can be found in the What’s New box on homepage.
- Contact your Senator to urge them to support AB 2100 (Wood) to fix Medi-Cal reimbursement today! -
The California Pharmacists Association is pleased to announce that AB 2100 (Wood) unanimously passed the Senate Health Committee without opposiiton. AB 2100 is now heading to the Senate Appropriations Committee and CPhA is calling on you to contact your elected Senator to urge passage of AB 2100.
AB 2100, which would make the necessary changes to Medi-Cal’s administration of the pharmacy benefit to its beneficiaries, in line with Governor Gavin Newsom’s objective of moving the pharmacy benefit out of Medi-Cal Managed Care and into fee-for-service (FFS) without causing undue harm or burden to patients.
AB 2100 also corrects the “below-acquisition cost” reimbursement issue caused by the newly adopted methodology mandated by the Affordable Care Act in 2016.
Find out from the California Board of Pharmacy's Executive Officer and CPhA’s General Counsel in this livestream webinar CE session on August 15.
Don’t miss out on this opportunity to hear from the industry experts on laws that affect you and your profession, all from the comfort of home. Earn 6 CE hours and 1 hour of CE to satisfy CA Code of Regulations §§ 1732.5(b).
You will learn about:
New laws affecting pharmacy practice
PBM & Medi-Cal audits and recoupments
Pharmacy operational compliance, policies & procedures, and more
Pharmacists' corresponding responsibility
Legal considerations for non-traditional practices such as cannabis, compounding, and collaborative practice agreements